The principal venture capital backer of ProStrakan, a Scottish drug development firm, has defended its decision to float the firm at a time of weak investor demand for new issues in the European biotechnology sector.

Warburg Pincus, a global private equity firm with a 44.4% stake in ProStrakan, said the loss-making company was confident the float would go ahead.